Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Sponsor: Celgene
Terminated
low accrual
Other terminated trials from Celgene
Other Urinary Bladder Neoplasms trials with similar outcome
Listed as NCT01342172, this PHASE1/PHASE2 trial focuses on Urinary Bladder Neoplasms and remains terminated or withdrawn. Sponsored by Celgene, it has been updated 12 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — May 2019 [monthly]
Terminated PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- Icahn School of Medicine at Mount Sinai
For direct contact, visit the study record on ClinicalTrials.gov .